Binding of benzodiazepines and some major metabolites at their sites in normal human frontal cortex in vitro

E. Richelson, A. Nelson, R. Neeper

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Using [3H]flunitrazepam in radioligand binding assays, we determined equilibrium dissociation constants (K(d)'s) at 37°C for 22 benzodiazepines (15 parent compounds and 7 major metabolites) at benzodiazepine binding sites in human frontal cortex. This list included several compounds never studied before at human receptors. Although dissociation was too rapid to measure reliably at this temperature, the K(d)'s for flunitrazepam were not significantly different when either rapid filtration or centrifugation was used to separate the bound from free radioligand. The most potent compound was triazolam (K(d) = 0.54 nM); the least potent, chlordiazepoxide (K(d) = 0.54 nM); the least potent, chlordiazepoxide (K(d) = 684 nM). The K(d)'s were significantly lower (about 3- to 7-fold) for several compounds tested at an equilibrium temperature of 0°C compared to those obtained at 37°C. There was a strong correlation for 15 compounds for the log K(d) at rat brain receptors (data obtained from the literature) vs. the log K(d) for human brain. In addition, the log K(d)'s of the various benzodiazepines for their receptor were significantly correlated with the log of their minimum daily dosages used to treat patients. Many of the benzodiazepines have clinically important active metabolites that have higher affinity for benzodiazepine binding sites in human brain than their parent compounds. Such data have important implications in the clinical use of these compounds.

Original languageEnglish (US)
Pages (from-to)897-901
Number of pages5
JournalJournal of Pharmacology and Experimental Therapeutics
Volume256
Issue number3
StatePublished - 1991

Fingerprint

Frontal Lobe
Benzodiazepines
Flunitrazepam
Chlordiazepoxide
Brain
Binding Sites
Triazolam
Radioligand Assay
Temperature
GABA-A Receptors
Centrifugation
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmacology

Cite this

Binding of benzodiazepines and some major metabolites at their sites in normal human frontal cortex in vitro. / Richelson, E.; Nelson, A.; Neeper, R.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 256, No. 3, 1991, p. 897-901.

Research output: Contribution to journalArticle

@article{cf21aa4cebcb4335bf81b9e1eb204624,
title = "Binding of benzodiazepines and some major metabolites at their sites in normal human frontal cortex in vitro",
abstract = "Using [3H]flunitrazepam in radioligand binding assays, we determined equilibrium dissociation constants (K(d)'s) at 37°C for 22 benzodiazepines (15 parent compounds and 7 major metabolites) at benzodiazepine binding sites in human frontal cortex. This list included several compounds never studied before at human receptors. Although dissociation was too rapid to measure reliably at this temperature, the K(d)'s for flunitrazepam were not significantly different when either rapid filtration or centrifugation was used to separate the bound from free radioligand. The most potent compound was triazolam (K(d) = 0.54 nM); the least potent, chlordiazepoxide (K(d) = 0.54 nM); the least potent, chlordiazepoxide (K(d) = 684 nM). The K(d)'s were significantly lower (about 3- to 7-fold) for several compounds tested at an equilibrium temperature of 0°C compared to those obtained at 37°C. There was a strong correlation for 15 compounds for the log K(d) at rat brain receptors (data obtained from the literature) vs. the log K(d) for human brain. In addition, the log K(d)'s of the various benzodiazepines for their receptor were significantly correlated with the log of their minimum daily dosages used to treat patients. Many of the benzodiazepines have clinically important active metabolites that have higher affinity for benzodiazepine binding sites in human brain than their parent compounds. Such data have important implications in the clinical use of these compounds.",
author = "E. Richelson and A. Nelson and R. Neeper",
year = "1991",
language = "English (US)",
volume = "256",
pages = "897--901",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Binding of benzodiazepines and some major metabolites at their sites in normal human frontal cortex in vitro

AU - Richelson, E.

AU - Nelson, A.

AU - Neeper, R.

PY - 1991

Y1 - 1991

N2 - Using [3H]flunitrazepam in radioligand binding assays, we determined equilibrium dissociation constants (K(d)'s) at 37°C for 22 benzodiazepines (15 parent compounds and 7 major metabolites) at benzodiazepine binding sites in human frontal cortex. This list included several compounds never studied before at human receptors. Although dissociation was too rapid to measure reliably at this temperature, the K(d)'s for flunitrazepam were not significantly different when either rapid filtration or centrifugation was used to separate the bound from free radioligand. The most potent compound was triazolam (K(d) = 0.54 nM); the least potent, chlordiazepoxide (K(d) = 0.54 nM); the least potent, chlordiazepoxide (K(d) = 684 nM). The K(d)'s were significantly lower (about 3- to 7-fold) for several compounds tested at an equilibrium temperature of 0°C compared to those obtained at 37°C. There was a strong correlation for 15 compounds for the log K(d) at rat brain receptors (data obtained from the literature) vs. the log K(d) for human brain. In addition, the log K(d)'s of the various benzodiazepines for their receptor were significantly correlated with the log of their minimum daily dosages used to treat patients. Many of the benzodiazepines have clinically important active metabolites that have higher affinity for benzodiazepine binding sites in human brain than their parent compounds. Such data have important implications in the clinical use of these compounds.

AB - Using [3H]flunitrazepam in radioligand binding assays, we determined equilibrium dissociation constants (K(d)'s) at 37°C for 22 benzodiazepines (15 parent compounds and 7 major metabolites) at benzodiazepine binding sites in human frontal cortex. This list included several compounds never studied before at human receptors. Although dissociation was too rapid to measure reliably at this temperature, the K(d)'s for flunitrazepam were not significantly different when either rapid filtration or centrifugation was used to separate the bound from free radioligand. The most potent compound was triazolam (K(d) = 0.54 nM); the least potent, chlordiazepoxide (K(d) = 0.54 nM); the least potent, chlordiazepoxide (K(d) = 684 nM). The K(d)'s were significantly lower (about 3- to 7-fold) for several compounds tested at an equilibrium temperature of 0°C compared to those obtained at 37°C. There was a strong correlation for 15 compounds for the log K(d) at rat brain receptors (data obtained from the literature) vs. the log K(d) for human brain. In addition, the log K(d)'s of the various benzodiazepines for their receptor were significantly correlated with the log of their minimum daily dosages used to treat patients. Many of the benzodiazepines have clinically important active metabolites that have higher affinity for benzodiazepine binding sites in human brain than their parent compounds. Such data have important implications in the clinical use of these compounds.

UR - http://www.scopus.com/inward/record.url?scp=0025904589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025904589&partnerID=8YFLogxK

M3 - Article

C2 - 1848631

AN - SCOPUS:0025904589

VL - 256

SP - 897

EP - 901

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -